Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (Third Affiliated Hospital, Sun Yat-Sen University)
- Development stage
- Unknown
- Lead developer
- The Third Affiliated Hospital of Sun Yat-sen University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
This investigational cell therapy consists of allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) developed by the Third Affiliated Hospital of Sun Yat-Sen University. It is primarily being evaluated for the treatment of various stages of spinal cord injury (SCI), including sub-acute, early chronic, and late-stage chronic phases. The therapy is administered via repeated intrathecal (subarachnoid) transplantation, typically at a dose of 1 × 10^6 cells/kg. The mechanism of action is multifaceted, involving the paracrine release of neurotrophic and beneficial factors, immunomodulation to inhibit inflammation, promotion of revascularization at the injury site, and regulation of apoptosis to facilitate neural repair and functional recovery.
- Other names
- hUC-MSCshuman umbilical cord mesenchymal stem cellsUC-MSCumbilical cord mesenchymal stem cells-Third Affiliated Hospital, Sun Yat-Sen University-spinal cord injury
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (Third Affiliated Hospital, Sun Yat-Sen University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Third Affiliated Hospital, Sun Yat-Sen University).